Advertisement

The Effect of Platelet-Derived Growth Factor on Tone and [Ca2+]i in Vascular Smooth Muscle

  • A. D. Hughes
Part of the Experimental Biology and Medicine book series (EBAM, volume 26)

Abstract

Platelet derived growth factor (PDGF) is a cationic protein first described in platelets (8). PDGF is now known to be produced by a variety of cell types including endothelial cells, vascular smooth muscle cells and macrophages/monocytes (reviewed in 4). PDGF exists in multiple molecular weight isoforms which are composed of two chains (A & B) which share considerable homology. All possible dimeric forms of PDGF have been described (PGDF-AA, PDGF-BB, PDGF-AB), although the dominant isoform produced varies depending on cell type and experimental conditions (4). PDGF is a potent mitogen for vascular smooth muscle cells (4, 13) and may account for 50% of the mitogenic action of platelets (6). PDGF also contracts vascular smooth muscle in some (2, 3), but not all sites (1). PDGF-induced vasoconstriction is reported to be unaffected by antagonists of α-adrenoceptors, 5HT2 receptors or cyclo-oxygenase (3) and presumably involves a direct action on the PDGF receptor, although the mechanism of this effect is unclear. PDGF interacts with a membrane associated receptor to induce receptor dimerization and autophosphorylation on multiple tyrosine sites (10). These phosphotyrosine residues can then interact with a variety of intracellular mediators by a process involving binding to SH2 domains in the effector proteins. Phospholipase C-γ, phosphatidyl-inositol-3 kinase, GTP-ase activating protien for p21 ras (GAP) and p21 ras all appear to be activated by PDGF in this way (10). The role of one or any of these systems in PDGF-induced contraction of vascular smooth muscle is unknown. Therefore this study examined the possible role of changes in intracellular Ca2+ (Cai) in the contractile action of PDGF in isolated rabbit ear artery using the fluorescent indicator fura-2 (14,15).

Keywords

Vascular Smooth Muscle Cell Platelet Derive Growth Factor Platelet Derive Growth Factor Receptor Dihydropyridine Calcium Antagonist Calcium Channel Current 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    BASSET, J.E., BOWEN-POPE, D.F., TAKAYASU, M., DACEY, R.G., JR. Platelet-derived growth factor does not constrict rat intracerebral arterieoles in vitro. Microvasc. Res. 35: 368–373, 1988.Google Scholar
  2. 2.
    BERK, B.C. AND ALEXANDER, R.W. Vasoactive effects of growth factors. Biochem. Pharmacol. 38: 219–225, 1989.PubMedCrossRefGoogle Scholar
  3. 3.
    BERK, B.B, ALEXANDER R.W., BROCK, T.A., GIMBRONE, M.A., JR AND WEBB, R.C. Vasoconstriction: a new activity for platelet-derived growth factor. Science 232: 87–90, 1986PubMedCrossRefGoogle Scholar
  4. 4.
    BOBIK, A., AND CAMPBELL, J.H. Vascular derived growth factors: cell biology, pathophysiology, and pharmacology. Pharmacol. Rev. 45: 1–42, 1993.PubMedGoogle Scholar
  5. 5.
    GRYNKIEWICZ, G., POENIE, M., TSIEN, R.Y. A new generation of Cal’ indicators with greatly improved fluorescence properties. J. Biol. Chem. 260: 3440–3450, 1985.PubMedGoogle Scholar
  6. 6.
    HELDIN, C.-H., WESTERMARK, B., AND WASTESON, A. Demonstration of and antibody against platelet-derived growth factor. Exp. Cell Res. 136: 255–261, 1981.PubMedCrossRefGoogle Scholar
  7. 7.
    KAWAHARA, Y., KARIYA, K-I., ARAKI, S-I., FUKUZAKI, H. AND TAKAI, Y. Platelet-derived growth factor (PDGF)-induced phospholipase C-mediated hydrolysis of phosphoinositides in vascular smooth muscle cells–different sensitivity of PDGF- and angiotenin II-induced phospholipase C reactions to protein kinase C-activating phorbol esters. Biochem. Biophys. Res. Commun. 156: 846–854, 1988.Google Scholar
  8. 8.
    KOHLER AND LIPTON A. Platelets as a source of fibroblast growth promoting activity. Exp. Cell Res. 87 (suppl 2), 297–310, 1974.CrossRefGoogle Scholar
  9. 9.
    MULVANY, M.J., HALPERN, W. Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circ.Res. 41: 19–26, 1977.PubMedCrossRefGoogle Scholar
  10. 10.
    PAZIN, M.J. AND WILLIAMS, L.T. Triggering signalling cascades by receptor tyrosine kinases. T.I.B.S. 17: 374–378, 1992.Google Scholar
  11. 11.
    ROE, M.W., LEMASTERS, J.J., HERMAN, B. Assessment of fura-2 for measurements of cytosolic free calcium. Cell Calcium 11: 63–73, 1990.PubMedCrossRefGoogle Scholar
  12. 12.
    ROSENGURT, E. Early signals in the mitogenic response. Science 234: 161–166, 1986CrossRefGoogle Scholar
  13. 13.
    ROSS, R., BOWEN POPE, D.F., RAINES, E.W. Platelet-derived growth factor and its role in health and disease. Philos.Trans. R. Soc. Lond. Biol. 327: 155–169, 1990PubMedCrossRefGoogle Scholar
  14. 14.
    TSIEN, R.Y. A non-disruptive technique for loading calcium buffers and indicators into cells. Nature 290: 527–528, 1981.PubMedCrossRefGoogle Scholar
  15. 15.
    TSIEN, R.Y. Fluorescent probes of cell signaling. Annu. Rev. Neurosci. 12: 227–253, 1989.CrossRefGoogle Scholar
  16. 16.
    WIJETUNGE, S., AALKJAER, C., SCHACHTER, M., HUGHES, A.D. Tyrosine kinase inhibitors block calcium channel currents in vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 189: 1620–1623, 1992.Google Scholar

Copyright information

© Springer Science+Business Media New York 1994

Authors and Affiliations

  • A. D. Hughes
    • 1
  1. 1.Department of Clinical PharmacologySt. Mary’s Hospital Medical SchoolLondonUK

Personalised recommendations